Last reviewed 2026-05-27 · How we verify

Ioglicinate (IOGLICIC ACID)

Phase 2 active Small molecule

Ioglicinate (generic name: IOGLICIC ACID) is a ioglicic acid drug. It is currently in Phase 2 development.

Ioglicinate works by binding to and inhibiting the activity of a specific enzyme or protein.

Ioglicinate, also known as ioglicic acid, is a small molecule drug of the ioglicic acid class. Its original development and current ownership are not specified in the provided facts. The target and approved indications of ioglicinate are unknown. Its commercial status, including patent status and generic availability, is also unclear. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is not available.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	IOGLICIC ACID
Drug class	ioglicic acid
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a key fitting into a lock - ioglicinate is the key that blocks the action of a particular enzyme, which is involved in a specific process in the body. This can help to prevent or treat certain conditions by altering the balance of chemicals in the body. By blocking the enzyme, ioglicinate can help to reduce the symptoms of a particular disease or condition.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ioglicinate CI brief — competitive landscape report
Ioglicinate updates RSS · CI watch RSS

Frequently asked questions about Ioglicinate

What is Ioglicinate?

Ioglicinate (IOGLICIC ACID) is a ioglicic acid drug.

How does Ioglicinate work?

Ioglicinate works by binding to and inhibiting the activity of a specific enzyme or protein.

What is the generic name of Ioglicinate?

IOGLICIC ACID is the generic (nonproprietary) name of Ioglicinate.

What drug class is Ioglicinate in?

Ioglicinate belongs to the ioglicic acid class. See all ioglicic acid drugs at /class/ioglicic-acid.

What development phase is Ioglicinate in?

Ioglicinate is in Phase 2.

Drug class: All ioglicic acid drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing